Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bexsero in Adolescents
NCT00661713Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2008
- Primary completion
- Apr 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease (8 arms), sponsored by Novartis. Primary endpoints: Percentages of Subjects With hSBA Titer >= 1:4 at Month 3 and Number of Subjects With Local Reactions and Systemic Reactions. Started Jun 2008; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00661713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00661713.